Dr. Abraham Daniel is a registered pharmacist with over 15 years of experience spanning community and hospital pharmacy, academic research, pharmaceutical industry roles, and regulatory affairs. He completed his PhD at the University of Tasmania in 2020, focusing on novel therapeutics for progressive vision loss.
Abraham has contributed to international healthcare initiatives, including USAID-funded programs in Africa, where he supported the management of medical commodities for HIV/AIDS and malaria. At the Therapeutic Goods Administration (TGA), he worked with the pharmacovigilance team, investigating medicine quality issues and adverse events to ensure the safety and efficacy of therapeutic goods.
Currently, Abraham supports regulatory strengthening and capacity-building initiatives across Southeast Asia and the Pacific, fostering collaboration to improve medicines quality and safety.